Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Complete | ||
Fosavance | Alendronate sodium/cholecalciferol | Osteoporosis | Do not list | Complete | ||
Fosavance 70/5600 | Alendronate sodium / cholecalciferol | Osteoporosis | List in a similar manner to other drugs in class | Complete | ||
Fosrenol | Lanthanum carbonate hydrate | Hyperphosphatemia, end-stage renal disease | Do not list | Complete | ||
Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | N/A | Complete | ||
Fycompa | Perampanel | Epilepsy, partial onset seizures | List with criteria/condition | Complete | ||
Fycompa | Perampanel | Epilepsy, primary generalized tonic-clonic seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
Galafold | migalastat | Fabry Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Galexos | Simeprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete |